Changes in Beneficial Ownership · 4
Keros Therapeutics, Inc.
KROSNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-08192026_040802.xml
Filing details
- Report period
- 2026-08-17
- Issuer
- Keros Therapeutics, Inc.
- Issuer CIK
- 0001664710
- Trading symbol
- KROS
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- BIENAIME JEAN JACQUES
- Reporting owner CIK
- 0001221590
- Relationship
- Director
- Address
- C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-17 | P · Form 4[F1] | 1,000 | A | 10.27[F2] | 19,592 | D |
Table key
- P · Form 4
- Purchase on the market or privately
- A
- Acquired
- D
- Direct
Footnotes
- F1
- Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.↩ 1
- F2
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.02 to $10.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.↩ 1
Signature 1
- Signed
- /s/ Esther Cho, Attorney-in-Fact
- Date
- 2026-08-19